Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) have earned a consensus rating of “Moderate Buy” from the eleven brokerages that are covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $26.8571.

Several brokerages recently issued reports on ZVRA. Weiss Ratings cut Zevra Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a report on Friday, May 22nd. UBS Group reissued a “buy” rating on shares of Zevra Therapeutics in a report on Wednesday, June 24th. Wall Street Zen upgraded Zevra Therapeutics from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Canaccord Genuity Group cut their price target on Zevra Therapeutics from $29.00 to $20.00 and set a “buy” rating for the company in a research note on Monday. Finally, Guggenheim cut their price target on Zevra Therapeutics from $29.00 to $24.00 and set a “buy” rating for the company in a research note on Monday.

Hedge Funds Weigh In On Zevra Therapeutics

Several hedge funds have recently added to or reduced their stakes in ZVRA. Stratos Wealth Partners LTD. lifted its holdings in shares of Zevra Therapeutics by 78.6% in the fourth quarter. Stratos Wealth Partners LTD. now owns 409,000 shares of the company’s stock valued at $3,665,000 after purchasing an additional 180,000 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of Zevra Therapeutics by 1,458.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 438,984 shares of the company’s stock worth $4,175,000 after purchasing an additional 410,823 shares in the last quarter. AIGH Capital Management LLC purchased a new position in shares of Zevra Therapeutics during the 1st quarter worth approximately $11,184,000. Hennion & Walsh Asset Management Inc. acquired a new position in shares of Zevra Therapeutics during the 4th quarter worth approximately $1,251,000. Finally, UBS Group AG raised its position in shares of Zevra Therapeutics by 30.9% during the 4th quarter. UBS Group AG now owns 285,488 shares of the company’s stock worth $2,558,000 after purchasing an additional 67,392 shares during the last quarter. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

Zevra Therapeutics Trading Down 1.3%

Shares of Zevra Therapeutics stock opened at $9.51 on Friday. The company has a 50-day moving average of $12.31 and a two-hundred day moving average of $10.50. Zevra Therapeutics has a 12-month low of $7.16 and a 12-month high of $15.03. The stock has a market cap of $562.23 million, a PE ratio of 4.78 and a beta of 0.85.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.18 EPS for the quarter, topping the consensus estimate of $0.06 by $0.12. The business had revenue of $36.22 million for the quarter, compared to analyst estimates of $31.96 million. Zevra Therapeutics had a return on equity of 51.49% and a net margin of 101.58%. On average, sell-side analysts forecast that Zevra Therapeutics will post 0.56 EPS for the current fiscal year.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.